Lilly hsits 485 jobs at its headquarters to pay for painful clinical failures

Medicines Network January 24 - Lilly's U.Sheadquarters recently sent a letter to the local labor development department, saying it will lay off 485 employees, mainly from The Lilly Alzheimer's business unitthe immediate result of Lilly's layoffs was the failure of Lilly's much-watched third large-scale Phase III EXPEDITION3 clinical study of the anti-beta amyloid therapy solaneb in November last year, and the failure of patients with mild lyme Alzheimer's to significantly delay cognitive dysgeneration compared to a placebo after taking the solanezumab portionthe failure led Lilly to re-evaluate its workforce, and in December 2016, Lilly informed its U.SBiopharmaceutical Group sales representative that it was preparing to lay off staff in the first quarter of 2017The letter also mentions that the redundancy order will take effect on March 31, after which affected employees can submit transfer requests for other positions within the companySolanzumab's unexpected gift to Lilly has been hurt enmassing in its journey to expand the future, but some of Lilly's high-margin best-selling products, such as Cialis, which treats erectile dysfunction, Strattera, which treats attention deficit and adhd, and the anti-thrombosis drug Effient, are also facing a growing number of competitorsSolanzumab's launch is expected to be a successor to the veterandrug, easing the competitive pressure on LillyIf Solanezumab doesn't succeed, Lilly will have to look to the market to stabilize with other new products, including the diabetes treatment drug Jardiance and Sanofigan's insulin-like drug Basaglar, investors are also pinning their hopes on key products such as baricitinib, an oral new drug for rheumatoid arthritis, toward the end of a Lilly clinical trialIn early 2016, Lilly filed an application for a new drug with the FDA, and long-term trial results demonstrated last June showed that the drug's effectiveness in preventing joint damage was up to dateBut just a few days ago, the FDA said it would take more than three months to examine the extra datanot just the Alzheimer's unit is about to face layoffs, and Lilly spokesman Edward Sagebiel said that veteran Lilly Elanco Animal Health could opt out voluntarily because of the need to adjust, with no details being given"These changes will simplify our operations while improving our execution and productivity." Elanco, theanimal health division, has been under fire for its poor performance in the third quarter of last year, amid speculation about whether Lilly will break up the animal health sector Lilly's Animal Health Division reported revenue of $706 million in the third quarter of last year, down 9 percent from a year earlier, and according to analysis, irregular pet health acquisitions and a sharp dive in animal food market demand under the guidance of retired CEO John Lechleiter, Lilly continues to build a product line for animal health , which bought BurlingEr's pet vaccine business for $885 million last October Li Lida has publicly stated that from Lilly's point of view, animal health is an important channel for expanding its product line, and has good synergy with the human product business So will the new CEO, David Ricks, continue this strategy? It is not yet known Lilly, , said the company would also close its biopharmaceutical business unit's health integration unit and the Cardiovascular Finance Commissioner's department